Search

1243 - 1251 of 2104 results

Joe Tonge

Activity Ambassador Joe Tongue discusses how weightlifting and bodybuilding has helped his cystic fibrosis (CF).

Search result from the Trials Tracker

A study of the combined effects of three CFTR modulator medicines in people with cystic fibrosis aged 12 and older (VX18-445-113)

In order to take part in this study you will already be taking part in the VX17-659-105 study, taking VX-659 with tezacaftor and ivacaftor. For this new study, you will switch to taking VX-445 instead of VX-659. Both combinations work in the same way. VX-445 is a medicine being studied for how well it works and how safe it is in people with cystic fibrosis. Your participation in this study will help us learn more about the long-term safety of VX-445 in combination with tezacaftor and ivacaftor. All three are CFTR modulators which means that they help the faulty CFTR...

Click below to find out more. Find out more

Trials Tracker ID: TT002066
Age range: 12 years and older
Trial status: Recruitment complete
Therapeutic approach: Restore CFTR Function

Search result from the Trials Tracker

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Adults With Cystic Fibrosis

In this study, the investigational CFTR modulator medicine PTI-808 will be given in combination with one or two other investigational modulator medicines, PTI-801 and PTI-428. PTI-428, PTI-801, and PTI-808 are considered cystic fibrosis transmembrane conductance regulator (CFTR) modulators being developed to treat the underlying cause of cystic fibrosis. PTI-428 is a CFTR amplifier that increases the amount of CFTR protein in the cell, PTI-801 is a CFTR corrector that improves the processing of CFTR protein in the cell, and PTI-808 is a CFTR potentiator to enhance the activity of CFTR at the cell surface. Modulators on their own have been...

Click below to find out more. Find out more

Trials Tracker ID: TT002061
Age range: 18+
Trial status: Closed with results
Therapeutic approach: Restore CFTR Function

Search result from the Trials Tracker

A study to learn more about a combination of CFTR modulator medicines in people with Cystic Fibrosis (VX 18 445 104)

This study is being done to learn more about a new medication called ‘VX-445’ when taken in combination with tezacaftor and ivacaftor. All three of these medications are known as CFTR modulators. CFTR modulators work to treat the underlying genetic cause of cystic fibrosis. This combination of medication is being assessed in people with Cystic Fibrosis who are 12 years and older and who are heterozygous for the F508del mutation and a gating or residual function mutation. The study will investigate how well these medications work and to check that they are safe to use. It is the hope that...

Participants in the group receiving Kaftrio had an average 3.5% higher lung function than the control group. They also had lower sweat chloride levels, which suggests higher CFTR function. There was no significant difference in the number of adverse events between the groups.

The results suggest Kaftrio is more effective than other existing modulator treatments. This supports Kaftrio being used as a treatment for people with these gene variants.

Click below to find out more. Find out more

Trials Tracker ID: TT002056
Age range: 12 years and older
Trial status: Closed with results
Therapeutic approach: Restore CFTR Function

Search result from the Trials Tracker

A study of the combined long-term effects of a triple combination CFTR modulator in people with cystic fibrosis aged 12 and older

In order to take part in this study you will already be taking part in the VX18-445-104 study. VX-445 is a medicine being studied for how well it works and how safe it is in people with cystic fibrosis (CF). Your participation in this study will help us learn more about how well VX-445 works in combination with tezacaftor and ivacaftor in people with CF with one copy of a CF gene with a mutation termed F508del and the other copy of a CF gene with a mutation termed gating or residual function. All three of the medicines are CFTR...

Click below to find out more. Find out more

Trials Tracker ID: TT002051
Age range: 12 years and older
Trial status: Recruitment complete
Therapeutic approach: Restore CFTR Function

Search result from the Trials Tracker

A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del (VX18-445-109)

This trial has been archived

A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Click below to find out more. Find out more

Trials Tracker ID: TT002046
Age range: 12 years and older
Trial status: Closed with results
Therapeutic approach: Restore CFTR Function

Search result from the Trials Tracker

A Phase 2 study of ABBV-3067 alone and in combination with ABBV-2222

This trial has been archived

In this study, participants will be given ABBV-3067 (“potentiator”) and ABBV-2222 (“corrector”) to see if treatment improves participants’ lung function. Different groups of participants will receive different doses, and some will receive a dummy drug (“placebo”). This study evaluates the safety and efficacy (how well the medications work) of the medications and the best dose of each medicine to be used in future studies. This is a Phase 2, double-blinded (treatment type is unknown to participants and investigators) study in people with CF who have two copies of the F508del mutation (the most common CFTR gene mutation). Participants go through...

Click below to find out more. Find out more

Trials Tracker ID: TT002041
Age range: 18 years and older
Trial status: Closed with results
Therapeutic approach: Restore CFTR Function

Search result from the Trials Tracker

A Study to Assess various doses of an ENaC inhibitor medication (mucociliary clearance) in Healthy Volunteers and People with Cystic Fibrosis

A study medication called ION-827359 is being developed to treat lung disease symptoms in people with cystic fibrosis. The study medication is intended to help treat the thick mucus found in the airways of patients with cystic fibrosis. This new inhaled (nebulized) medication will be investigated in both people with, and without cystic fibrosis. The study will compare the study medication with a placebo (a solution that looks identical to the study medication but contains no active ingredients), which means some participants will receive the study medication, whilst others will receive the placebo. Participants won’t know whether they are receiving...

Click below to find out more. Find out more

Trials Tracker ID: TT002031
Age range: 18 years and older
Trial status: Closed with results
Therapeutic approach: Mucociliary Clearance

Search result from the Trials Tracker

High Flow Nasal Therapy during exercise in CF

High flow nasal therapy (HFNT) is a way to deliver a mixture of air and oxygen at higher flows compared to standard oxygen therapy. It has been shown to improve oxygenation, reduce breathlessness and breathing rate, and is quite comfortable. Recently HFNT has been shown to improve exercise capacity and tolerance in patients with other lung diseases. HFNT is routinely used in clinical practice in patients with CF who present acutely unwell during hospital admissions. We believe that HFNT could be used by patients with CF during exercise in order to improve their tolerance, lengthen their exercise sessions, and allow...

Click below to find out more. Find out more

Trials Tracker ID: TT002026
Age range: 18 years and older
Trial status: Closed with results
Therapeutic approach: Other